#USA #Rome #CRISPR #Functional Genomics #IRBM

IRBM Expands Functional Genomics Platform

IRBM, a renowned Contract Research Organization (CRO) specializing in preclinical drug discovery, has recently introduced a comprehensive Functional Genomics Platform. This innovative platform aims to streamline the identification and validation of genetic targets essential for drug development, facilitating the creation of relevant cellular models for various diseases.

Advancements in Genomic Editing

To further improve target validation, IRBM is enhancing its genomic editing toolkit with advanced CRISPR techniques. These techniques will systematically map functional domains within both coding and regulatory regions of genes. Additionally, the incorporation of base and prime editing methods allows for precise nucleotide modifications. By combining these next-generation approaches, along with high-throughput CRISPR screening that includes stem cell engineering, IRBM is well-positioned to construct robust disease models and enhance the reliability of target validation.

Sara Tomaselli, PhD, Head of Functional Genomics at IRBM, stated, "Understanding which targets are truly viable for drug development poses a complex challenge. With this internal platform, we bolster our capability to systematically assess gene functions, minimize the risks of early-stage discoveries, and empower our partners to make well-informed decisions."

Comprehensive Screening Capabilities

The platform's screening capabilities encompass CRISPR libraries for genomic knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa). This breadth allows for an exhaustive exploration of gene function and associated pathways. Furthermore, IRBM's expertise in cellular engineering includes patient-relevant models and systems derived from induced pluripotent stem cells (iPSC), which aid in modeling diseases such as oncology, neurodegeneration, and rare diseases.

IRBM's approach integrates multi-omics strategies, incorporating high-content imaging, single-cell transcriptomics, and proteomics to provide deeper functional characterization of drug targets. The Functional Genomics Platform is part of a broader and fully integrated ecosystem for drug discovery, ensuring that genetic insights are translated into meaningful preclinical models and drug development strategies.

Synergistic Collaboration

By merging functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM empowers biopharmaceutical innovators to tackle target validation with enhanced confidence. Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM, remarked, "We adopt a meticulous and thoughtful approach to functional genomics that seamlessly integrates with the complexities of drug discovery. Our goal is to assist our partners in discovering high-quality targets and generating data to guide decision-making throughout the drug discovery process."

Working with Biotech Startups

IRBM’s collaborative approach enables biotech startups, pharmaceutical companies, and venture capital teams to access functional genomics expertise without the need for internal infrastructure. With tailored solutions encompassing genetic screening, cellular model engineering, and mechanistic studies, IRBM offers practical, scientifically rigorous support at critical junctures in drug discovery.

For more information on IRBM's Functional Genomics Platform and collaboration opportunities, please visit IRBM's website.

About IRBM

IRBM is a contract research organization focused on early-stage drug discovery. With a proven track record in developing preclinical candidates in oncology, neurodegeneration, and infectious diseases, IRBM collaborates with biotech and pharmaceutical innovators to drive therapeutic development with scientific precision and transparency.